Cingulate Inc. (CING)
Market Closed
12 Dec, 20:00
NASDAQ (CM) NASDAQ (CM) Primary $
4. 42
+0.24
+5.74%
$
20.57M Market Cap
- P/E Ratio
0% Div Yield
211,954 Volume
-3.21 Eps
$ 4.18
Previous Close Day Range
4.15 4.48
Year Range
3.2 6.01
Want to track CING and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Cingulate stock surges 115% after European patent approval for ADHD treatment: Is it a buy?
Cingulate Inc (NASDAQ: CING), a biopharmaceutical firm specializing in innovative ADHD treatments, experienced a remarkable surge in its stock price on Friday, with shares skyrocketing by 115%. This dramatic increase is attributed to the company's recent achievement of securing a European patent for CTx-1301, its flagship ADHD treatment.
Invezz | 1 year ago
2025 © Marketlog. All Rights Reserved.
